The “Blockbuster Dilemma” in Biotech
We studied ~10 commercial-stage companies and learned about this interesting theme. Amgen, Genentech, Biogen, Regeneron, Vertex, Gilead, Celgene, Abbvie...
Biodraft_
Biodraft_ is a biotech blog started by Liang Chang (PhD student at Broad/Harvard) and Kirill Karlin, MD (pathology resident at BIDMC/HMS). As trainees in science/medicine and students in biotechs, we post our monthly biotech analysis on various topics.
Subscribe:.rss.atom.json.md.m3u.pls
Dormant Last read · last published · next check
Read 10 days ago and current, but nothing has been published for 4 years.
Latest episodes
Deep-dive into platform biotech companies: phenotypes, business models, destinations...
We studied over 30 platform companies and share what we have learned. Moderna, Alnylam, Intellia, Recursion, Ginkgo, Kite, Genentech...
Therapeutics around the central dogma: DNA
A study note on gene therapy and gene editing landscape: MoA and delivery
Welcome to Biodraft!
A short readme about our biotech blog